Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
- Author:
Marta BRASCHI-AMIRFARZAN
1
;
Sree Harsha TIRUMANI
;
Frank Stephen Jr HODI
;
Mizuki NISHINO
Author Information
- Publication Type:Review
- Keywords: Immune-checkpoint inhibitor; Toxicity; Response; Immune-related Response Criteria
- MeSH: Antibodies; Cell Death; Hematologic Neoplasms; Immune System; Precision Medicine*; T-Lymphocytes, Cytotoxic
- From:Korean Journal of Radiology 2017;18(1):42-53
- CountryRepublic of Korea
- Language:English
- Abstract: Over the past five years immune-checkpoint inhibitors have dramatically changed the therapeutic landscape of advanced solid and hematologic malignancies. The currently approved immune-checkpoint inhibitors include antibodies to cytotoxic T-lymphocyte antigen-4, programmed cell death (PD-1), and programmed cell death ligand (PD-L1 and PD-L2). Response to immune-checkpoint inhibitors is evaluated on imaging using the immune-related response criteria. Activation of immune system results in a unique toxicity profile termed immune-related adverse events. This article will review the molecular mechanism, clinical applications, imaging of immune-related response patterns and adverse events associated with immune-checkpoint inhibitors.
